InMed (INM) director files Form 3: 3,500 options at $2.1
InMed Pharmaceuticals (INM) reported an initial statement of beneficial ownership by a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals (INM) reported an initial statement of beneficial ownership by a director. The filing lists an employee stock option to purchase 3,500 common shares at an exercise price of $2.1, with an expiration date of 10/16/2030.
The event date is 10/14/2025. According to the vesting terms, the options were granted on 10/17/2025 and will vest monthly, in arrears: 98 options on the 17th of each month for 35 months, and 70 options on 10/17/2025. Ownership is reported as Direct.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- F1. The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did InMed (INM) disclose in this Form 3?
What is the vesting schedule for the INM options?
What role does the reporting person have at INM?
What is the date of the event requiring this statement?
How are the options held according to the filing?
What class of securities underlies the derivative?
AI-generated analysis. How Rhea-AI works. Not financial advice.